



Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome

OPEN ACCESS

Edited by:

Alexandre Belot, Université Claude Bernard Lyon 1, France

Reviewed by:

Sébastien VIEL, UMR5308 Centre International de Recherche en Infectiologie (CIRI), France Pierre Sujobert, Hospices Civils de Lyon, France

*Correspondence:

Rik Schrijvers rik.schrijvers@uzleuven.be

[†]These authors have contributed equally to this work

Specialty section:

This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology

Received: 10 March 2021 Accepted: 08 April 2021 Published: 23 April 2021

Citation:

Staels F, Betrains A, Woei-A-Jin FJSH, Boeckx N, Beckers M, Bervoets A, Willemsen M, Neerinckx B, Humblet-Baron S, Blockmans DE, Vanderschueren S and Schrijvers R (2021) Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome. Front. Immunol. 12:678927. doi: 10.3389/fimmu.2021.678927 Frederik Staels^{1,2†}, Albrecht Betrains^{3,4†}, F. J. Sherida H. Woei-A-Jin^{5,6†}, Nancy Boeckx^{7,8}, Marielle Beckers^{8,9}, An Bervoets^{10,11}, Mathijs Willemsen^{1,12}, Barbara Neerinckx^{13,14}, Stephanie Humblet-Baron¹, Daniel Engelbert Blockmans^{3,4}, Steven Vanderschueren^{3,4†} and Rik Schrijvers^{1,2,3*†}

¹ Laboratory of Adaptive Immunology, Immunology and Transplantation, Department of Microbiology, KU Leuven, Leuven, Belgium, ² Allergy and Clinical Immunology Research Group, Immunology and Transplantation, Department of Microbiology, KU Leuven, Leuven, Belgium, ³ Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium, ⁴ Laboratory of Clinical Infectious and Inflammatory Disease, Immunology and Transplantation, Department of Microbiology, KU Leuven, Leuven, Belgium, ⁵ Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium, ⁶ Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven, Belgium, ⁷ Clinical Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium, ⁸ Laboratory of Experimental Hematology, Department of Oncology, KU Leuven, Leuven, Belgium, ⁹ Department of Hematology, University Hospitals Leuven, Leuven, Belgium, ¹⁰ Department of Dermatology, University Hospitals Leuven, Leuven, Belgium, ¹¹ Department of Dermatology, University Hospitals Antwerpen, Edegern, Belgium, ¹² VIB-KU Leuven Center for Brain and Disease Research, KU Leuven, Leuven, Belgium, ¹³ Department of Rheumatology, University Hospitals Leuven, Belgium, ¹⁴ Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium

Recently, a novel disorder coined VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome was identified in patients with adult-onset inflammatory syndromes, often accompanied by myelodysplastic syndrome1. All patients had myeloid lineage-restricted somatic mutations in UBA1 affecting the Met41 residue of the protein and resulting in decreased cellular ubiquitylation activity and hyperinflammation. We here describe the clinical disease course of two VEXAS syndrome patients with somatic UBA1 mutations of which one with a mild phenotype characterized by recurrent rash and symmetric polyarthritis, and another who was initially diagnosed with idiopathic multicentric Castleman disease and developed macrophage activation syndrome as a complication of the VEXAS syndrome. The latter patients was treated with anti-IL6 therapy (siltuximab) leading to a resolution of systemic symptoms and reduction of transfusion requirements.

Keywords: primary immunodeficiencies, autoinflammation, treatment reactions, myelodysplasia, ubiquitination

1

INTRODUCTION

Recently, a novel disorder named VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome was identified in patients with adult-onset inflammatory syndromes, often accompanied by myelodysplastic syndrome (MDS) (1). All patients had myeloid lineage-restricted somatic mutations in UBA1 affecting the Met41 residue of the protein. This promotes the production of an inactive isoform (UBA1c) from a downstream translation site (Met67), resulting in decreased ubiquitylation activity and hyperinflammation (1).

We describe the clinical disease course of two VEXAS syndrome patients (P1 and P2) with two different myeloid lineage-restricted somatic UBA1 mutations (Figure 1A). One of these patients was initially diagnosed with idiopathic multicentric Castleman disease (iMCD) and was ultimately treated with siltuximab, a registered IL-6 antagonist.

CASE DESCRIPTION

Patient 1 (Figure 1A and Table 1) is a 69-year-old male with a medical history of an abdominal hernia for which he had surgery. He presented with 15 kg weight loss over one year, fever up to 38.2° Celsius, night sweats and fatigue since one month, bilateral cervical lymphadenopathy, arthralgia, episcleritis, nose chondritis, thrombophlebitis and nodular lesions (Figure 1B.I-V). Laboratory examination showed normocytic anemia (Hb 6.6g/dL, MCV 96fL; reference range 76-96fL), absolute neutrophil count

 $2.2 \ge 10^{9}$ /L, thrombocytopenia 46 $\ge 10^{9}$ /L and raised inflammatory markers (CRP 93.1mg/L, normal <5mg/L; ferritin 720µg/L, reference range 30-400µg/L). Cervical lymph node excision biopsy was suggestive of human herpes virus (HHV-)8-negative plasma cell type iMCD and additionally showed hemophagocytosis, while skin nodule biopsy demonstrated subendothelial complement depositions consistent with vasculopathy. Bone marrow examination at diagnosis (Figure 1C and Table 1) showed trilineage dysplasia with vacuolization and hemophagocytosis (CD68+). Reticulin staining was mildly positive indicating the presence of myelofibrosis (MF grade 1 according to the WHO 2016 classification criteria). Six out of eight hemophagocytic lymphohistiocytosis (HLH)-2004 criteria were fulfilled confirming the diagnosis of HLH. As siltuximab is not reimbursed in Belgium, the patient was treated for iMCD with prednisolone 40 mg and 2 infusions of rituximab (1000 mg) with a time interval of 2 weeks. As corticosteroids could not be tapered and the patient remained transfusion dependent, sirolimus was initiated in second line with good results. However, the patient relapsed quickly after cessation of sirolimus because of toxic concentrations and opportunistic infections. He developed confusion, dyspnea, high grade fever >40°Celsius, complement-mediated vasculopathy with skin ulcerations, anemia (Hb 6.3g/dL, severe thrombocytopenia 3 x 10⁹/L with bleeding complications, and ferritin levels of 3640µg/L (partly due to >28 units red blood cell transfusions). The patient was started on siltuximab (in medical need) and prednisolone 10 mg/day in third line. This resulted in resolution of fever, skin lesions, and normalization of inflammatory markers. From hindsight, serum IL-6 was significantly elevated (102pg/mL,





TABLE 1 | Summary of the demographics, genetic and clinical characteristics, bone marrow examination, and treatment response of the VEXAS patients.

Demographic/genetic S9 75 Age of onset 69 75 UBAT inutation p.Met41Th* p.Met411Leu Clinical spectrum and laboratory findings at presentation Macrocytic anemia Macrocytic anemia Leukopenia Delyclonal hypergammaglobulinemia Polyclonal hypergammaglobulinemia Lymphoproliferation Carvical upmbadenopathy - Lymphoproliferation Splenomegaly - Constitutional Fever Fedgue Raised inflammatory markers Raised inflammatory markers Haised inflammatory markers Huporterintinemia Hyperferminemia Hyperferminemia Mucocutaneous Periodultis-like nodular lesions Uncertal vasculitis Musculoskeletal Arbraigia Symmetric polyathritis Musculoskeletal Arbraigia Symmetric polyathritis Musculoskeletal Moderately cellular Nomocylic secondaria Musculoskeletal Moderately cellular Nomocylic secondaria Musculoskeletal Moderately cellular Nomocylic secondaria Musculoskeletal Moderately cellular <t< th=""><th></th><th>Patient 1</th><th>Patient 2</th></t<>		Patient 1	Patient 2
Age of misster 69 75 UBA1 mutation p.Met41 Thr p.Met41 Lau Clinical spectrum and laboratory findings at presentation Macrocytic anemia Hematopoietic Normocytic anemia Macrocytic anemia Lukukopenia Providenia Providenia Trromopoenia Trromopoenia - Constitutional Fever Fever Fatigue Fatigue Fatigue Ngint Sweats - - Ngint Sweats - - Muccoutaneous Panniculitie-like noclular lesions Uncertinenia Muscoutaneous Panniculitie-like noclular lesions Uncertinenia Muscoutaketetal Arthraigia Symmetric polyarthritis Muscoutaketetal Nase chondritis Easter filtis Muscoutaketetal Macrocytice and dysplasia Macrocytica parametric polyarthritis Muscoutaketetal Macrocytice and dysplasia Mysoid vacuulation on advina Muscoutaketetal Macrocytica and dysplasia Mysoid vacuulation and dysplasia Muscoutaketetal Macrocytica and dysplasia Mysoid vacuulation and dysplasia Muscoutaketetal Macrocytica and dysplasia Mysoid vacuulation and dysplasia Muscoutaketetal Macrocytica parametay cellular Normocollular </th <th>Demographic/genetic</th> <th></th> <th></th>	Demographic/genetic		
ÚDe1 mutation p.Met41Thr p.Met41Thr Clinical spectrum and laboratory findings at present Macrocytic anemia Macrocytic anemia Leukopenia Polycional hypergammagiobulinemia Lumphoponia Thrombopenia Lymphoproliferation Cervical hypehadenopathy – Constitutional Pever Feuer Patigue Fatigue Fatigue Weight loss usert – Night vesats – – Mucocutaneous Panicultis-like nodular lesions Uricarial vascultis Uncol trained Episcleritis Severe skin reaction to anakima Ophthalmologic Appresentimemia Hyperferminemia Muscubskeletal Athralgia Symmetric polyarthritis Other Thrombophiebitis Severe skin reaction to anakima Muscubskeletal Mathralgia Mathralgia Muscubskeletal Mathralgia Mathralgia Muscubskeletal Mathralgia Mathralgia Muscubskeletal Mathralgia Nometric polyarthritis Muscubskeletal Mathralgia Nometric polyarthritis Muscubskeletal Mathralgia Nometric polyarthritis Muscubskeletal Mathralgia Nometric polyarthritis Muscubs	Age of onset	69	75
Clinical spectrum and laboratory findings at presentation Marrocytic anemia Macrocytic anemia Hematopoletic Normocytic anemia Polyclonial Polyclonial Lymphopenia Turombopenia Turombopenia Turombopenia Fever - Constitutional Gervical lymphodenopathy - Partonegaly - Constitutional Fever Fetugue Raised inflammatory markers Raised inflammatory markers Night sweats - Nucocutaneous Panicultis-like nodular lesions Uticatel vasculitis Mucocutaneous Episclenitis Severe skin reaction to anakinra Ophthalmologic Episclenitis Severe skin reaction to anakinra Musculoskeletal Arthralgia Symmetric polyarthritis Musculoskeletal Arthralgia Symmetric polyarthritis Morocutaneous Horomobphesis Deep venous thrombosis Musculoskeletal Moderately cellular Normocellular Musculoskeletal Moderately cellular Normocellular Musculoskeletal Normocellular Normocellular Musculoskeletal Normocellular Normocellular Musculoskeletal Normocellular Normocellular Musculoskeletal Normocell	UBA1 mutation	p.Met41Thr	p.Met41Leu
Hematopoletic Normocytic anemia Leukopenia Leukopenia Lymphopenia Macrocytic anemia Polyclonal hypergammaglobulinemia Lymphoproliferation Carvical lymphadenopathy - Constitutional Cervical lymphadenopathy - Splenomegaly Ferver Fatigue Fatigue Weight loss Weight loss Weight loss Weight loss Weight loss Mucocutaneous Panicultis-like nodular lesions Urlicardi vascultis Ophthalmologic Episcleritis Swere skin reaction to anakinra Musculoskeletal Arthralgia Symmetric polyathritis Other Thrombophisis Deep venous thromboais Other Thrombophisis Deep venous thromboais Musculoskeletal Moderately cellular Nomocolicar and dysplasia Other Thrombophisitis Deep venous thromboais Masculoskeletal Moderately cellular Nomocolicar and dysplasia Myelici vasculization and dysplasia Dyserythropolesis Deep venous thromboais Musculoskeletal Not evaluable due to folc acid deficiency No Musculosteroids* Not evaluable due to folc acid deficiency No Mosculosteroids* Prednisona 60mg (+) Intilition (-) Mut-Th/F - Andrinra (-)	Clinical spectrum and laboratory finding	s at presentation	
Laukopénia Lymphopenia Lymphopenia Lymphopenia Lymphopenia Trombopenia Lymphopenia Trombopenia Lymphopenia Trombopenia Cenvical (mphadenopathy - Fever Fatigue Fever Fatigue Vegint loss Night sweats Fatigue Vegint loss Night sweats Fatigue Popentinemia	Hematopoietic	Normocytic anemia	Macrocytic anemia
Lymphopraliferation Grvical lymphadenopathy – – Splenomegaly – – Splenomegaly – – Splenomegaly – – Fatigue Fatigue Fatigue – – Fatigue Veight loss – – Raised inflammatory markers – – Raised inflammatory markers – – – – – – – – – – – – – – – – – – –		Leukopenia	Polyclonal hypergammaglobulinemia
Lymphoproliferation Cervical (mphodenopathy – – Spenomegaly – – Constitutional Fever – Fever – – Failgue – – – – – – – – – – – – – – – – – – –		Lymphopenia	
Lymphoproliferation Cervical ymphadenopathy – – Splenomegaly Fever Fever Fever Fever Fever Fever Faigue Reserver Faigue Fever Faigue Faigue Faigue Weight loss Lymperferminemia Phyperferminemia Phyperferminemia Phyperferminemia Chyperferminemia Chyperferminemia Phyperferminemia Chyperferminemia Chiperferminemia C		Thrombopenia	
Splenomegaly Constitutional Splenomegaly Fever Fever Fever Faitgue Fever Faitgue Veight loss Veight lo	Lymphoproliferation	Cervical lymphadenopathy	_
Constitutional Fever Fever Fatgue Fatgue Fatgue Fatgue Fatgue Fatgue Weight loss Weight loss Weight loss Night sweats - - Raised inflammatory markers Raised inflammatory markers Hyperferitivernia Mucocutaneous Panniculitis-like nodular lesions Urticarial vasculitis Livedo reticularis Severe skin reaction to anakinra Ophthalmologic Episcleritis Severe skin reaction to anakinra Musculoskeletal Nose chondritis Severe skin reaction to anakinra Other Thrombophebitis Deep venous thrombosis Masculoskeletal Nose chondritis Deep venous thrombosis Musculoskeletal Moderately cellular Nomocellular Musculoskeletal Nomocellular Myeloid vacuolization and dysplasia Dyserythropoiesis Dyserythropoiesis Dyserythropoiesis Muscu		Splenomegalv	
Fatigue Fatigue Fatigue Fatigue Weight Icss Weight Icss Nuccoutaneous - Muccoutaneous Hyperferritinemia Muccoutaneous Episcleritis-like nodular lesions Ophthalmologic Episcleritis Musculoskeletal Arthralgia Musculoskeletal Arthralgia Other Thrombophlebtiis Bone marrow examination Moderately cellular Myelid vacuolization and dysplasia Dyself vacuolization and dysplasia Dyserythropolesis Micromegakaryocytes Muscolostaroids* Not evaluable due to folic acid deficiency Not Criterial/type Musc Not evaluable due to folic acid deficiency Not - Criterial/type Not evaluable due to folic acid deficiency Not - Criterial/type Not evaluable due to folic acid deficiency Not - Criterial/type Not evaluable due to folic acid deficiency Not - Criterial/type Prednisone 60mg (+) Anti-IL-1 - Anti-IL-1 - Anti-IL-1 - Anti-IL-1 - Anti-IL-1 - Criterial/t	Constitutional	Fever	Fever
Weight loss Weight loss Night sweats - Raised inflammatory markers Haised inflammatory markers Hyperferritinemia Hyperferritinemia Mucocutaneous Pannicultiis-like nodular lesions Urticarial vasculitis Livedor reticularis Evedor reticularis Evedor reticularis Gohthalmologic Episcleritis Severe skin reaction to anakinra Musculoskeletal Antralgia Symmetric polyarthritis Musculoskeletal Nose chondritis Ear chondritis Other Thrombophilebitis Nose chondritis Masculoskeletal Moderately cellular Normocellular Musculoskeletal Maschillar Normocellular Musculoskeletal Moderately cellular Normocellular Musculoskeletal Moderately cellular Normocellular Musculoskeletal Moderately cellular Normocellular Myeidor vaculization and dysplasia Dyserythropolesis Mosculozation and dysplasia Dyserythropolesis Myeidor vaculization and dysplasia Moderately cellular Normocellular Karjotype		Fatique	Fatigue
Night sweats		Weight loss	Weight loss
Raised inflammatory markers Raised inflammatory markers Mucocutaneous Hyperferritinemia Mucocutaneous Phyperferritinemia Potholulis-like nodular lesions Livedo reticularis Severe skin reaction to anakinra Episcleritis Musculoskeletal Arthralgia Symmetric polyarthritis Musculoskeletal Arthralgia Symmetric polyarthritis Other Thrombophlebitis Deep venous thrombosis Moreately cellular None chondritis Deep venous thrombosis Moreately cellular Moderately cellular Normocellular Moreately cellular Myeloid vacuolization and dysplasia Dyserythropolesis Moreately cellular Moderately cellular Normocellular Mose chondritis Dyserythropolesis Dyserythropolesis Moserytopic (SDB8 +) Plasmocytosis (6%) Plasmocytosis (6%) MDS Erterial type 46, XY[10] 46, XY[10] NGS DNMT3A (c.1014+1G>T) VAF 31-46% Negative Treatment (response) - - Corticosteroids* Prednisolne 60mg (+) - Anti-L1-6 - - - Other Situximab (+) - - Other Situximab (+) - - <		Night sweats	-
Hyperferritinemia Hyperferritinemia Hyperferritinemia Mucocutaneous Panniculitis-like nodular lesions Uritoarial vasculitis Ophthalmologic Episcleritis Severe skin reaction to anakinra Musculoskeletal Arthraigia Symmetric polyarthritis Musculoskeletal Arthraigia Symmetric polyarthritis Musculoskeletal Cohordritis Ear chondritis Nose chondritis Deep venous thrombosis Nose chondritis Other Thrombophlebitis Deep venous thrombosis Masc/HLH Pulmonary embolism Moderately cellular Noreocellular Noreocellular Myeloid vacuolization and dysplasia Dyserythropolesis Dyserythropolesis Moreoregakaryocytes Hemophagocytes (CD68 +) Plasmocytes (6%) MDS Erteriativpe Keyative Karyotype Karyotype 46, XY[10] VAF 31-46% Negative Nosterrol - Anti-IL-1 - Anti-IL-16 Prednisone 60mg (+) - - Other Rituximab (-) - - Other Rituximab (-) -		Raised inflammatory markers	Baised inflammatory markers
Mucocutaneous Panniculitis-like nodular lesions Uniticarial vasculitis Mucocutaneous Panniculitis-like nodular lesions Livedo reticularis Ophthalmologic Episcleritis Severe skin reaction to anakinra Musculoskeletal Arthralgia Symmetric polyarthritis Musculoskeletal Arthralgia Nose chondritis Other Thrombophlebitis Deep venous thrombosis Mas/HLH Pulmonary embolism Normocellular Mydeloid vacuolization and dysplasia Dyserythropolesis Dyserythropolesis Micromegakaryocytes Atypical plasmocytes Hernophagocytosis (CD68 +) Plasmocytosis (6%) MDS Erietaristype 46, XY[10] 46, XY[10] Kayative NGS DNMT3A (c.1014+1G>T) VAF 31-46% Vegative Treatment (response) Corticosteroids* Prednisone 60mg (+) - Anakinra (-) Antri-IVF – Influximab (-) - Antri-IL-1 – Anakinra (-) - <t< td=""><td>Hyperferritinemia</td><td>Hyperferritinemia</td></t<>		Hyperferritinemia	Hyperferritinemia
Ophthalmologic Episcientis Livedo reticularis Musculoskeletal Arthralgia Episcientis Musculoskeletal Arthralgia Symmetric polyarthritis Other Thrombophlebitis Ear chondritis Other Thrombophlebitis Deep venous thrombosis MAS/HLH Pulmonary embolism Bone marrow examination Moderately cellular Norrocellular Myeloid vacuolization and dysplasia Dyserythropoiesis Myeloid vacuolization and dysplasia Diserverthropoiesis Micromegakaryocytes Atypical plasmocytes MBS Hemophagocytosis (CD68 +) Plasmocytosis (6%) MDS Teratiment (response) Not evaluable due to folic acid deficiency No Criteria/type Ac, XY[10] 4c, XY[10] No NGS DINIT3A (c.1014+1G>T) VAF 31-46% Negative Treatment (response) – Infliximab (-) Corticosteroids* Prednisone 60mg (+) – Anakinra (-) Anti-IL-1 – Anakinra (-) – Anakinra (-) Anti-IL-6 Situximab (+) – – – – <t< td=""><td rowspan="3">Mucocutaneous</td><td>Panniculitis-like nodular lesions</td><td>Urticarial vasculitis</td></t<>	Mucocutaneous	Panniculitis-like nodular lesions	Urticarial vasculitis
Ophthalmologic Episcleritis Severe skin reaction to anakinra Musculoskeletal Arthralgia Episcleritis Musculoskeletal Arthralgia Symmetric polyarthritis Nose chondritis Ear chondritis Ear chondritis Other Thrombophlebitis Deep venous thrombosis Bone marrow examination Moderately cellular Nomocellular Myeloid vacuolization and dysplasia Myeloid vacuolization and dysplasia Dyserythropoiesis Dyserythropoiesis Dyserythropoiesis Dyserythropoiesis MCoromegakaryocytes Hemophagocytosis (CD68 +) Plasmocytosis (6%) MDS Eriestaritype Not evaluable due to folic acid deficiency No Karyotype 46, XY[10] 46, XY[10] Karyotype NGS DNMT3A (c.1014+1G>T) VAF 31-46% Negative Treatment (response) Corticosteroids* Prednisone 60mg (+) Infliximab (-) Infliximab (-) Anti-IL-1 – Anakinra (-)			Livedo reticularis
Ophthalmologic Episcleritis Episcleritis Musculoskeletal Arthralgia Symmetric polyarthritis Musculoskeletal Arthralgia Symmetric polyarthritis Musculoskeletal Arthralgia Symmetric polyarthritis Musculoskeletal Arthralgia Symmetric polyarthritis Other Thrombophlebitis Deep venous thrombosis MAS/HLH Pulmonary embolism Moreartely cellular Moreoelluar Myeloid vacuolization and dysplasia Myeloid vacuolization and dysplasia Dyserythropoiesis Dyserythropoiesis Dyserythropoiesis Micromegagaryccytes Atypical plasmocytes Hore Criteria/type Not evaluable due to folic acid deficiency No Karyotype 46, XY[10] 46, XY[10] NGS DNIT34 (c.1014+1G>T) VAF 31-46% Negative Treatment (response)			Severe skin reaction to anakinra
Musculoskeletal Arthralgia Symmetric polyarthritis Musculoskeletal Nose chondritis Nose chondritis Nose chondritis Nose chondritis Nose chondritis Other Thrombophlebitis Deep venous thrombosis MAS/HLH Pulmonary embolism Bone marrow examination Moderately cellular Normocellular Myeloid vacuolization and dysplasia Myeloid vacuolization and dysplasia Dyserythropoiesis Micromegakarycocytes Atprical plasmocytes Hemophagocytosis (CD68 +) Plasmocytosis (6%) MDS Eriterialtype Not evaluable due to folic acid deficiency No Karyotype Veloid vacuolit+1G>T) VAF 31-46% Negative Treatment (response)	Ophthalmologic	Episcleritis	Episcleritis
Nose chondritis Ear chondritis Other Thrombophlebitis Deep venous thrombosis MAS/HLH Pulmonary embolism Bone marrow examination Moderately cellular Norrocellular Myeloid vacuolization and dysplasia Myeloid vacuolization and dysplasia Dyserythropoiesis Dyserythropoiesis Dyserythropoiesis Atypical plasmocytes MCromegakaryocytes Atypical plasmocytes Atypical plasmocytes Moderately cellular Veloid vacuolization and dysplasia Veloid vacuolization and dysplasia Dyserythropoiesis Dyserythropoiesis Myeloid vacuolization and dysplasia MDS Erriteria/type Atypical plasmocytes Criteria/type Not evaluable due to folic acid deficiency No Karyotype 46, XY[10] 46, XY[10] NGS DNMT3A (c.1014+1G>T) VAF 31-46% Negative Treatment (response) — — Corticosteroids* Prednisone 60mg (+) — Anti-TI/F — — Anti-TI/F — — Anti-TI/F — — Other Sitruximab (-) — Sitruximab (-) _ — Anti-TI/F — — Other Sitruximab (-) _ </td <td rowspan="3">Musculoskeletal</td> <td>Arthralgia</td> <td>Symmetric polyarthritis</td>	Musculoskeletal	Arthralgia	Symmetric polyarthritis
Other Thrombophlebitis Deep venous thrombosis MAS/HLH Pulmonary embolism Bone marrow examination Moderately cellular Normocellular Myeloid vacuolization and dysplasia Dyserythropoiesis Dyserythropoiesis Dyserythropoiesis Moderately cellular Atypical plasmocytes MDS Hemophagocytosis (CD68 +) Plasmocytosis (6%) MDS Vertreative valuable due to folic acid deficiency No Karyotype 46, XY[10] 46, XY[10] NGS DNMT3A (c.1014+1G>T) VAF 31-46% Negative Treatment (response)		Nose chondritis	Ear chondritis
Other Thrombophlebitis Deep venous thrombosis MAS/HLH Pulmonary embolism Bone marrow examination Moderately cellular Normocellular Myeloid vacuolization and dysplasia Myeloid vacuolization and dysplasia Dyserythropoiesis Dyserythropoiesis Micromegakaryocytes Atypical plasmocytes Hemophagocytosis (CD68 +) Plasmocytosis (6%) MDS Criteria/type Not evaluable due to folic acid deficiency No Karyotype 46, XY[10] 46, XY[10] NGS DMMT3A (c.1014+1G>T) VAF 31-46% Negative Treatment (response)			Nose chondritis
MAS/HLH Pulmonary embolism Bone marrow examination Moderately cellular Normocellular Myeloid vacuolization and dysplasia Myeloid vacuolization and dysplasia Dyserythropoiesis Dyserythropoiesis Micromegakaryocytes Atypical plasmocytes Hemophagocytosis (CD68 +) Plasmocytosis (6%) MDS Criteria/type Not evaluable due to folic acid deficiency No Karyotype 46, XY[10] 46, XY[10] Mogative NGS DINMT3A (c.1014+1G>T) VAF 31-46% Negative Treatment (response) – Infliximab (-) Corticosteroids* Prednisone 60mg (+) Prednisolene 10mg (+) Anti-TNF – Anakinra (-) Anti-IL-6 Siltuximab (+) – Other Rituxinab (-) Leflunomide (-) Coldbicine (-) Coldbicine (-) Coldbicine (-)	Other Bone marrow examination	Thrombophlebitis	Deep venous thrombosis
Bone marrow examination Noderately cellular Nomocellular Myeloid vacuolization and dysplasia Myeloid vacuolization and dysplasia Dyserythropoiesis Dyserythropoiesis Dyserythropoiesis Dyserythropoiesis Micromegakaryocytes Atypical plasmocytes Hemophagocytosis (CD68 +) Plasmocytosis (6%) MDS Criteria/type No Karyotype 46, XY[10] No NGS DNMT3A (c.1014+1G>T) VAF 31-46% Negative Treatment (response) - Infliximab (-) Anti-TNF - Anakinra (-) Anti-TNF - Anakinra (-) Anti-LL-6 Siltuximab (+) - Other Rituximab (-) Leffunomide (-) Colchicine (-) Colchicine (-) Colchicine (-)		MAS/HI H	Pulmonary embolism
Myeloid vacuolization and dysplasia Myeloid vacuolization and dysplasia Myeloid vacuolization and dysplasia Dyserythropoiesis Micromegakaryocytes Atypical plasmocytes Hemophagocytosis (CD68 +) Plasmocytosis (6%) MDS Volexitype Criteria/type Not evaluable due to folic acid deficiency No Karyotype 46, XY[10] 46, XY[10] NGS DNMT3A (c.1014+1G>T) VAF 31-46% Negative Treatment (response) Volicone 60mg (+) Prednisolone 10mg (+) Anti-TNF – Infliximab (-) Anti-IL-1 – Anakinra (-) Anti-IL-6 Siltuximab (+) – Other Rituximab (-) Methotrexate (-) Sirolimus (+) Leflunomide (-) Colchicine (-)		Moderately cellular	Normocellular
Dyserythropolesis Dyserythropolesis Dyserythropolesis Micromegakaryocytes Atypical plasmocytes Hemophagocytosis (CD68 +) Plasmocytes MDS Volume Criteria/type Not evaluable due to folic acid deficiency No Karyotype 46, XY[10] 46, XY[10] NGS DNMT3A (c.1014+1G>T) VAF 31-46% Negative Treatment (response) Volume Volume Corticosteroids* Prednisone 60mg (+) Prednisolone 10mg (+) Anti-TNF – Infliximab (-) Anti-IL-1 – Anakinra (-) Anti-IL-6 Siltuximab (+) – Other Rituximab (-) Leflunomide (-) Sirolimus (+) Leflunomide (-) Colchicine (-)		Myeloid vacuolization and dysplasia	Myeloid vacuolization and dysplasia
Micromegakaryocytes Atypical plasmocytes Micromegakaryocytes Atypical plasmocytes Homophagocytosis (CD68 +) Plasmocytosis (6%) MDS Criteria/type Not evaluable due to folic acid deficiency No Karyotype 46, XY[10] 46, XY[10] 46, XY[10] NGS DNMT3A (c.1014+1G>T) VAF 31-46% Negative Treatment (response)		Dyserythronoiesis	Dyservthropolesis
Million regard (or place) Plasmocytosis (6%) MDS E Criteria/type Not evaluable due to folic acid deficiency No Karyotype 46, XY[10] 46, XY[10] NGS DNMT3A (c.1014+1G>T) VAF 31-46% Negative Treatment (response) E E Corticosteroids* Prednisone 60mg (+) Prednisolone 10mg (+) Anti-TNF – Infliximab (-) Anti-IL-1 – Anakinra (-) Anti-IL-6 Siltuximab (+) – Other Rituximab (-) Leflunomide (-) Sirolimus (+) Leflunomide (-) Colchicine (-)		Micromegakarvocytes	Atvoical plasmocytes
MDS Criteria/type Not evaluable due to folic acid deficiency No Karyotype 46, XY[10] 46, XY[10] NGS DNMT3A (c.1014+1G>T) VAF 31-46% Negative Treatment (response) Prednisolne 60mg (+) Prednisolne 10mg (+) Anti-TNF _ Infliximab (-) Anakinra (-) Anti-IL-1 _ Anakinra (-) Other Siltuximab (-) _ _ Sirolimus (+) Leflunomide (-) Colchicine (-)		Hemophagocytosis (CD68 +)	Plasmocytosis (6%)
Criteria/type Not evaluable due to folic acid deficiency No Karyotype 46, XY[10] 46, XY[10] NGS DNMT3A (c.1014+1G>T) VAF 31-46% Negative Treatment (response) Prednisone 60mg (+) Prednisolone 10mg (+) Anti-TNF – Infliximab (-) Anti-IL-1 – Ankira (-) Other Siltuximab (-) – Bituximab (-) – – Cituation (-) Endinomide (-) Colchicine (-)	MDS		
Karyotype 46, XY[10] 46, XY[10] NGS DNMT3A (c.1014+1G>T) VAF 31-46% Negative Treatment (response) Corticosteroids* Prednisone 60mg (+) Anti-TNF – Infliximab (-) Anti-IL-1 – Anakinra (-) Anti-IL-6 Siltuximab (-) – Other Rituximab (-) – Sirolimus (+) Leflunomide (-) Colocicione (-) Colocicione (-)	Criteria/type	Not evaluable due to folic acid deficiency	No
NGS DNMT3A (c.1014+1G>T) VAF 31-46% Negative Treatment (response) Prednisolne 60mg (+) Prednisolone 10mg (+) Anti-TNF – Infliximab (-) Anti-IL-1 – Anakirra (-) Other Siltuximab (-) – Sirolimus (+) Leflunomide (-) Colchicine (-)	Karvotype	46 XY[10]	46 XY[10]
Treatment (response) Corticosteroids* Prednisone 60mg (+) Prednisolone 10mg (+) Infliximab (-) Anti-TNF - Infliximab (-) Anti-IL-1 Anti-IL-6 Siltuximab (+) Colchoine (-) Sirolimus (+) Colchoine (-) Colchoine (-)	NGS	DNMT3A (c 1014+1G>T) VAE 31-46%	Negative
Corticosteroids* Prednisone 60mg (+) Prednisolone 10mg (+) Anti-TNF - Infliximab (-) Anti-IL-1 - Anakinra (-) Anti-IL-6 Siltuximab (+) - Other Rituximab (-) Methotrexate (-) Sirolimus (+) Leflunomide (-) Colchicine (-) Colchicine (-)	Treatment (response)		. togailto
Anti-TNF – Infliximab (-) Anti-IL-1 – Anakinra (-) Anti-IL-6 Siltuximab (+) – – Other Rituximab (-) Methotrexate (-) Sirolimus (+) Leflunomide (-) Colchicine (-)	Corticosteroids*	Prednisone 60mg (+)	Prednisolone 10mg (+)
Anti-IL-1 – Anakina (-) Anti-IL-6 Siltuximab (+) – – Other Rituximab (-) Methotrexate (-) Sirolimus (+) Leflunomide (-) Colchicine (-)	Anti-TNF		Infliximab (-)
Anti-IL-6 Siltuximab (+) – Other Rituximab (-) Methotrexate (-) Sirolimus (+) Leflunomide (-) Colchicine (-)	Anti-IL-1	_	Anakinra (-)
Other Rituximab (-) Methotrexate (-) Sirolimus (+) Leflunomide (-) Colchicine (-) Colchicine (-)	Anti-IL-6	Siltuximab (+)	-
Sirolimus (+) Leflummide (-) Colchicine (-)	Other	Rituximab (-)	Methotrexate (-)
Colchicine (-)		Sirolimus (+)	Leflunomide (-)
			Colchicine (-)

*Minimal dose with clinical response; +, clinical response; -, no clinical response; HLH, hemophagocytic lymphohistiocytosis; MAS, macrophage activation syndrome; MDS, myelodysplastic syndrome; NGS, next generation sequencing.

healthy controls <9.5pg/mL, n = 6) prior to siltuximab treatment. Although the patient became less transfusion dependent, his platelets and hemoglobin levels only partially recovered following 2 months of treatment.

Patient 2 (**Figure 1A** and **Table 1**) is a 76-year-old male. His medical history is significant for deep venous thrombosis with pulmonary embolism and type B aortic dissection. He presented with a recurrent rash and a symmetric polyarthritis of both large and small joints (**Figure 1B**.VI–VII). He had no fever and symptoms were rather mild. Laboratory examination showed macrocytic anemia and raised inflammatory markers (CRP 280.9mg/L; ferritin 1161µg/L). Skin biopsy revealed urticarial vasculitis. Bone marrow examination (**Figure 1C** and **Table 1**) showed trilineage dysplasia with myeloid vacuolization and reactive plasmocytosis without evidence of a plasma cell dyscrasia. He was treated with a tapering regimen of corticosteroids, relapsed at a dose of 7.5 mg prednisolone and was subsequently initiated on methotrexate (MTX) 15 mg weekly. Three months later, he developed a bilateral episcleritis for which he received topical indomethacin. Since symptoms were refractory to MTX in combination with prednisolone, anakinra (100 mg daily S.C.) was given for a suspected undifferentiated autoinflammatory syndrome. This resulted in a pronounced, delayed injection site reaction characterized by erythematous infiltrated plaques and subsequent treatment cessation. Considering the inability of tapering the prednisolone below 10 mg daily, anti-TNF- α therapy was initiated. Following the infliximab loading regimen, prednisolone could be reduced to 5 mg daily. Subsequently, the patient developed polyarthritis, a livedoid rash, and polychondritis of the nose and ears, requiring dosage increment to 10 mg prednisolone to remain disease free with subclinical signs of biochemical inflammation.

DISCUSSION

The two VEXAS patients recently diagnosed within our academic hospital demonstrated a phenotype consistent with the recently described cohort by Beck et al. Both patients had myeloid vacuolization, chondritis and a systemic inflammatory disease state. VEXAS was initially reported to be a highly refractory disease to diverse biologicals (anti-TNF-α, anti-CD20; anti-IL1, anti-IL17 therapy, CTLA4 agonist) only responding to high dose corticosteroids (1). However a recent report on the therapeutic options in VEXAS patients, evaluating the time to next treatment as an objective marker, suggested promising results for the use of JAK inhibitors (ruxolitinib or tofacitinib) in 3 VEXAS patients. One patient under JAK inhibition had markedly regression of cutaneous lesions without increment of corticosteroid dose (2). In neither of the treated patients, an improvement was seen in cytopenia and bone marrow myelodysplastic features. In patient 2, we observed a severe skin reaction to anakinra, which was more pronounced than expected. Severe skin reactions to anakinra were reported by Beck et al. in 62% of patients and may potentially provide a diagnostic clue. Interestingly, patient P1 with relapsing complement-mediated vasculopathy, who responded only to high dose corticosteroid treatment and sirolimus, benefited from siltuximab associated to low dose prednisolone with complete resolution of his inflammatory disease state. After genetic testing revealed VEXAS syndrome, the tentative diagnosis of Castleman disease was reconsidered.

Macrophage activation syndrome (MAS), a form of HLH, is a well-known complication of autoinflammatory disorders (3). MAS in the context of an autoinflammatory condition requires treatment of the underlying disorder, which is challenging in the therapy-refractory VEXAS syndrome (3). The VEXAS syndrome-related inflammatory manifestations in P1 resolved completely following siltuximab treatment. In addition, HLHcriteria were no longer met. This is in contrast with the findings by Beck et al., who reported a lack of response to tocilizumab treatment. Bourbon et al. on the other hand observed some responses to tocilizumab as well as azacytidine, cyclosporine, and JAK inhibitors (2). Siltuximab binds IL-6 itself rather than its receptor as is the case with tocilizumab. Similar unexpected disparities in response were reported previously for infliximab, an anti-TNF- α antibody vs. etanercept, targeting TNF- α as a decoy receptor (4).

In conclusion, the clinical spectrum of somatic UBA1 mutations may vary from a relatively easily low-dose prednisolone-treated VEXAS syndrome to a life-threatening MAS. We extend on the spectrum of cutaneous and hematologic manifestations associated with VEXAS syndrome. Finally, based on our observations, treatment of VEXAS syndrome with siltuximab warrants further evaluation in the absence of evidence-based recommendations. Corroborating the clinical response with additional cytokine measurements before and during treatment could further identify key cytokines and

delineate potential targets (1). In line, the pathophysiology of anakinra-induced adverse reactions in VEXAS remains elusive and might benefit from additional cytokine analysis.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/**Supplementary Material**.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the ethics committee of University Hospitals Leuven. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s), and minor(s)' legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

FS, AlB, SW-A-J, SV, and RS contributed to conception and design of the study. FS and MW performed the experiments for genetic validation and cytokin measurements. SW-A-J and NB performed histopathological evaluation of the bone marrow specimens. AlB, FS, and SW-A-J wrote the first draft of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

FS (11B5520N) is fellow of the Fonds Wetenschappelijk Onderzoek - Vlaanderen National Fund for Scientific Research (FWO). RS is FWO senior clinical investigator fellows (1805518N, respectively) and received funding from KU Leuven C1 (C12/16/024). SH-B and RS are supported by the VIB Grand Challenge program (Translational science initiative on PID, GC01-C01). DB, SV, and RS are members of the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (Project ID No 739543).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.678927/full#supplementary-material

REFERENCES

- Beck DB, Ferrada MA, Sikora KA, Ombrello K, Collins JC, Pei W, et al. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med (2020) 383(27):2628–38. doi: 10.1056/NEJM oa2026834
- Bourbon E, Heiblig M, Gerfaud-Valentin M, Barba T, Durel CA, Lega JC, et al. Therapeutic Options in Vexas Syndrome: Insights From a Retrospective Series. *Blood* (2021). doi: 10.1182/blood.2020010177
- Carter SJ, Tattersall RS, Ramanan AV. Macrophage Activation Syndrome in Adults: Recent Advances in Pathophysiology, Diagnosis and Treatment. *Rheumatology* (2019) 58(1):5–17. doi: 10.1093/rheu matology/key006
- Mpofu S, Fatima F, Moots RJ. Anti-TNF-α Therapies: They are All the Same (Aren't They?). *Rheumatology* (2005) 44(3):271–3. doi: 10.1093/rheumatology/keh483

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Staels, Betrains, Woei-A-Jin, Boeckx, Beckers, Bervoets, Willemsen, Neerinckx, Humblet-Baron, Blockmans, Vanderschueren and Schrijvers. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.